cyrilzakka/clinical-trials huggingface dataset:
Effects of Clomiphene Citrate Ovulation Induction on Frozen Embryo Transfer

Clomiphene citrate has been widely used for treatment of infertility for decades. Although its anti-estrogenic effects leads to low pregnancy rate, clomiphene citrate is still a first-line treatment for ovulation induction because of its simple usage, low prices, no injection and low risk of ovarian hyperstimulation syndrome. Clomiphene citrate shows high affinity with estrogen receptor, which inhibits endometrial proliferation, inevitably leads to a decline in endometrial receptivity, thus affecting the success rate of IVF.

In that case, use clomiphene citrate for ovulation induction is lost more than gained based on fresh embryo transfer. But recently, some researchers have proposed to extend the time from ovulation induction to embryo transfer, and the increased level of estradiol can replace clomiphene citrate to combine with the receptor, so that the uterine environment is more conducive to pregnancy. Therefore, use clomiphene citrate based on vitrification of embryo maybe a good way for treatment of infertility.

At present, using frozen embryo transplantation after ovulation induction by clomiphene citrate is a common treatment, but few research has mentioned the best time for embryo implantation. The investigators research is to find the most appropriate time for frozen embryo implantation after using clomiphene citrate for ovulation induction.

This study receives patients from 2017 August to 2018 June who undergo ART treatment at Shanghai Jiai Genetics \& IVF Institute and taken either CC or GnRH antagonist protocol(control group) for ovulation induction.

The investigators will record every patients' age, BMI, serum E2, P, LH level, infertility factors and pregnancy outcomes, counted the implantation rate and clinical pregnancy rate, and then used SPSS Software x2 test for statistical analysis, the significance was set at p\<0.05.The investigators will also make a correlation analysis about the serum hormone level and pregnancy outcomes.

Eligibility Criteria:
Inclusion Criteria:

Women 18-40 years of age who are scheduled for IVF or ICSI in our IVF institute while meeting the following criteria:

1. AMH ≥ 2;
2. Infertility factors: tubal factor, severe oligospermia, etc;
3. FET cycle;
4. Cleavage stage embryo transfer (Day 3).

Exclusion Criteria:

1. BMI ≤ 18.4 or ≥ 25.0;
2. Have pregnancy complications;
3. Genital tract malformations, uterine cavity diseases, PCOS;
4. Endometriosis;
5. Genetic diseases, severe somatic diseases, mental disorder.
Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRD

Various drugs have been added to different treatment regimens in order to improve the response rate in patients with Acute Lymphoblastic Leukemia, however, it has been shown that adding Bortezomib to the relapsing regimen improves the proportion of second complete remissions without increasing chemotherapy toxicity. Therefore, proteasome inhibitors can drastically modify the prognosis of patients, since their synergy with drugs such as steroids has positioned them as an attractive strategy.

Mortality associated with leukemia has decreased due to the use of various chemotherapy combinations, the addition of new agents, or the chemical modification of existing drugs. Despite advances in treatment, the prognosis in the adult population continues to be unfavorable. About 25% of the patients will be refractory to the first treatment regimen and the rest will have a disease-free survival below 40%. The chemotherapy intensity reduction strategy based on risk stratification according to Minimal Residual Disease (MRD) is a strategy used by various pediatric centers in order to detect patients at high risk of relapse.

Eligibility Criteria:
Inclusion Criteria:

* Patients with a confirmatory diagnosis of Acute Lymphoblastic Leukemia relapsed to bone marrow described with more than 5% blasts in bone marrow at any stage of treatment or positivity of minimal residual disease at any stage of treatment.
* Patients who have signed their informed consent from the institution for hospitalization, and accepted the performance of the bone marrow study, and the administration of chemotherapy.

Exclusion Criteria:

* Patients with a diagnosis of phenotypic leukemia or bilinear leukemia
* Patients treated only with palliative regimen or transfusion support
* Patients without the administration of prophylaxis to the central nervous system by intrathecal chemotherapy
* Patients with lymphoblastic leukemia with a positive Philadelphia chromosome
* Patients with severe comorbidities may put treatment therapy at risk.
* Patient with a history of cardiac toxicity or arrhythmias associated with treatment
Systemic Erythropoietin Injection in Patients Having Optic Atrophy

The purpose of this treatment trial is to study the effect of systemic erythropoietin in patients having optic atrophy.

The purpose of this treatment trial is to study the effect of systemic erythropoietin in patients having optic atrophy. The intervention is systemic erythropoietin injections (eprax 10000 IU subcutaneous twice daily for three days).

Follow up after one month and three months by recording visual acuity and electro physiological studies.

Eligibility Criteria:
Inclusion Criteria:

* Post papilledemic optic atrophy patients

Exclusion Criteria:

* Refuse to give an informed consent
Impact of Biosynthetic Mesh on Paraesophageal Hernia Repair

The aim of this study is to find out if using a certain kind of mesh can reduce the chances of hiatal hernias coming back after anti-reflux surgery. Participants undergoing antireflux surgery will be assigned to one of two groups, a group that has surgery with mesh, or a group that has surgery without mesh.


Eligibility Criteria:
Inclusion Criteria:

* Documented diagnosis of gastroesophageal reflux disease
* Adults aged 18 years or older
* English speaking
* Subject is planned to undergo surgery for reflux disease

Exclusion Criteria:

* Physician deems the subject is unable to complete the study due to documented dementia.
* Subject is undergoing emergent surgery.
* Pregnancy
* Patient has known allergy to tetracycline hydrochloride or kanamycin sulfate
Clinical Effect of No-touch Harvesting Technique in OPCABG

This study aims to investigate the clinical effect of the new saphenous vein harvesting technique "No-touch" in off-pump coronary artery bypass grafting(OPCABG), comparing to the conventional technique. Adopting CTA to evaluate the 3 months patency of the graft, we will compare veins harvested using No-touch technique to saphenous veins using conventional open technique.

Coronary artery disease(CAD) is a widespread health issue around the world. It is proven that atherosclerosis is a inflammatory disease, and endothelial dysfunction is one of the key factors that initiates the inflammatory response. Accumulating studies indicate that endothelial homeostasis plays a primordial role in the development of atherosclerosis.

Coronary artery bypass grafting(CABG) is the standard treatment of three-vessel or left main coronary artery disease, and its long-term benefits is apparent. Saphenous vein is the most common graft in CABG, however, the long-term patency is only about 50% in one year, as a result, it is urgent to discover a solution to improve the long term potency of vein grafts.

Conventional harvesting technique dissects the perivascular tissue and inject saline to check leakage, which causes damages to the endothelium of the vein, initiating inflammatory response. No-touch technique is a atraumatic, non-distended harvesting technique. According to the criteria, we will randomize the patients into two groups, the conventional and No-touch group, the vein will be used in sequential anastomosis, by comparing the 3 months patency rate assessed by CTA, we aim to compare the clinical outcomes of the two different vein harvesting techniques.

Eligibility Criteria:
Inclusion Criteria:

* patients from northern China
* first time isolated off-pump coronary artery bypass graft
* echocardiogram show that ejection fraction is over 35%
* the diameter of saphenous vein ≥ 2mm
* the vein graft will be used in sequential anastomosis, and the anastomosis sites ≥2
* be able to sign informed consent form

Exclusion Criteria:

* patients who need to undergo urgent surgery
* Severe renal insufficiency(creatinine \>200 umol/L)
* allergic to radiocontrast agent
* vein is used to isolated anastomosis
* Combined with malignant tumor or other severe systemic conditions
Teplizumab for Prevention of Type 1 Diabetes In Relatives "At-Risk"

The study will determine whether the anti-CD3 monoclonal antibody, teplizumab, can help to prevent or delay the onset of type 1 diabetes (T1D) in relatives determined to be at very high risk for developing the disease. Teplizumab has been studied in new onset type 1 diabetes for testing of efficacy and safety in previous studies; other studies are currently in progress. The results of previous studies indicate that teplizumab reduces the loss of insulin production during the first year after diagnosis in individuals with type 1 diabetes. The purpose of this study is to determine if teplizumab can interdict the immune process that causes the destruction of insulin secreting beta cells in the pancreas during the "pre-diabetic" state and thereby prevent or delay the onset of type 1 diabetes.

The study plans to enroll approximately 71 subjects between the ages of 8-45 years, over 2-3 years. The study is projected to last between 4-6 years, depending upon rate of enrollment and number of subjects who develop diabetes.

The main study objective is to determine whether intervention with teplizumab will prevent or delay the development of type 1 diabetes in high risk autoantibody positive non-diabetic relatives of individuals with T1D. Secondary outcomes are to include analyses of C-peptide and other measures from Oral Glucose Tolerance Testing (OGTT), safety, tolerability, and other mechanistic outcomes will be assessed during the study.

Eligibility Criteria:
Inclusion Criteria:

* Between ages of 8-45 years
* Have a relative with type 1 diabetes
* If first degree relative must be 8-45 years old (brother, sister, parent, offspring)
* If second degree relative must be between 8-20 years old (niece, nephew, aunt, uncle, grandchild, cousin)
* Abnormal glucose tolerance by OGTT confirmed with 7 weeks of baseline visit \[fasting blood glucose greater than 110mg/dL or and less than 126 mg/dL OR 2 hour glucose greater or equal to 140 mg/dL and less than 200 mg/dL OR 30, 60, or 90 minute value on OGTT greater than or equal to 200 mg/dL\]
* Presence of at least two confirmed diabetes autoantibodies

Exclusion Criteria:

* type 1 diabetes previously diagnosed or detected at screening \[fasting glucose greater or equal to 126 mg/dL or 2 hour glucose greater or equal to 200 mg/dL\]
* abnormalities in blood counts, liver enzymes, international normalised ratio (INR),
* positive purified protein derivative (PPD) test

  * vaccination with live virus within 6 weeks of randomization
* evidence of acute infection based on laboratory testing or clinical evidence
* serological evidence of past current or past HIV , hepatitis B, or hepatitis C infection
* Be currently pregnant or lactating
* Prior treatment with study drug
* Prior treatment with other monoclonal antibody in past one year
A Comparative, Controlled Study to Evaluate the Lay User Accuracy and Performance of the Dip Home-Based Dipstick Analyzer

The Dip Home-Based Dipstick Analyzer (henceforth HBDA) is composed of a kit and a smartphone application. The device will be provided to the subject in a simulated home-use environment. All subjects will be asked to complete the urine test by following the application guidance, including providing a urine sample and scanning the urine strip after placing it on the Color-Board.

The user will also complete a questionnaire to collect information regarding the use of the HBDA device. Following the usability test performed by the lay user, the subject's urine sample will be tested by the professional user using the comparator device. The use of the HBDA device will be evaluated for accuracy and identified risks. Additionally, measurable usability criteria for specific, critical steps will be evaluated.


Eligibility Criteria:
Inclusion Criteria:

* Men and women 18-80 years of age
* Subjects who are healthy or pregnant; or
* Subjects diagnosed with a disease that normally represents itself with an abnormal concentration of one of the following urine analytes; Glucose, Bilirubin, Ketone (Acetoacetic acid), Specific Gravity, Blood, pH, Protein, Urobilinogen, Leukocytes, and Nitrite
* Subject is capable and willing to provide informed consent.
* Subject has facility with both hands.
* Subject is capable and willing to adhere to the study procedures
Pediatric Zylet Safety and Efficacy Study

A multicenter study to evaluate the safety and efficacy of Zylet compared to vehicle in children aged 0-6 for the management of lid inflammation (chalazion/hordeolum)


Eligibility Criteria:
Inclusion Criteria:

* Child, 0 to 6 years of age, any sex and race
* Subject must have a clinical diagnosis of lid inflammation (e.g. Chalazion/Hordeolum) in at least one eye. If both eyes are diagnosed with lid inflammation, both eyes will be treated
* In good health (no current or past relevant medical history), based on the judgment of the investigator
* Parent/guardian is able and willing to follow instructions and provide informed consent

Exclusion Criteria:

* Known hypersensitivity to corticosteroids, loteprednol etabonate, or any component of the study medication
* Known hypersensitivity to aminoglycosides, tobramycin, or any component of the study medication
* Use of concurrent ocular therapy with non-steroidal anti-inflammatory agent (NSAID), mast cell stabilizer, antihistamine, or decongestant within 48 hours before and during the study
* Use of oral or topical ophthalmic corticosteroids (other than study medication) within 48 hours before and during the study
* Use of systemic antibiotics within 72 hours before and during the 14 day study medication treatment duration
* Use of topical ophthalmic antibiotics (other than the study medication) within 72 hours before and during the study
* History of ocular surgery, including laser procedures, within the past six months
* Anticipation that surgical intervention for lid inflammation will be required prior to completion of the study
* Subjects with suspected vernal conjunctivitis, glaucoma of any kind, viral or bacterial conjunctivitis, preseptal cellulitis requiring systemic antibiotics, dacryocystitis, uveitis, or any other disease conditions that could interfere with the safety and efficacy evaluations of the study medication
* History of any severe/serious ocular pathology or medical condition that could result in the subject's inability to complete the study
* Participation in an ophthalmic drug or device research study within 30 days prior to entry in this study
* Unlikely to comply with the protocol instructions for any reason
Efficacy of a Red Yeast Rice Based Nutraceutical Plus Probiotic in Patients With Moderate Hypercholesterolemia

A randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy of a red yeast rice based nutraceutical (monacolin K 10 mg/dose) plus probiotic (Bifidobacterium longum BB536 ®), versus placebo, in patients with moderate hypercholesterolemia, in terms of improvement of the lipid profile and cardiovascular risk.


Eligibility Criteria:
Inclusion Criteria:

* 18 ≤ men or women ≤ 70
* men or female. Female must be postmenopausal or surgically sterile
* 130 mg/dl ≤ LDL-C ≤ 200 mg/dl
* patients in primary cardiovascular prevention

Exclusion Criteria:

* pregnancy and lactating
* patients with chronic diseases
* patients with serious hepatic diseases
* patients with serious renal diseases
* patients with thyroid diseases
* diabetes mellitus or glycemia \>126 mg/dl
* uncontrolled or severe hypertension
* obesity(BMI\>30)
* smoking status
* drug or nutraceutical that can interfere with the experimental treatment
Comparison of Recovery From General Anesthesia in Remimazolam With Flumazenil vs. Propofol

This prospective randomized trial aims to compare recovery time from discontinuation of remimazolam followed by flumazenil administration vs. propofol-based total intravenous anesthesia in patients undergoing breast cancer surgery.

Adult patients undergoing breast cancer surgery are randomized to receive either remimazolam with flumazenil or propofol-based total intravenous anesthesia. When the surgery is ended, anesthetic agents are discontinued. The study's primary outcome is a comparison of the time to the first eye-opening response to the doctor's command from the discontinuation of anesthetic agents between the groups. Secondary outcomes include the time from anesthetics off to extubation/discharge from operating room (OR), BIS score at eye-opening/extubation/discharge from OR, the incidence of emergence agitation at OR, the PAT score, the modified Aldrete score, modified OAA/S (Observers Assessment of Alertness/Sedation Scale) after PACU administration. In addition, the investigators investigate postoperative pain score at 10/20/30 minutes and postoperative nausea and vomiting after PACU administration, Korean version of quality of recovery-15 in postoperative 24 hours, postoperative pain score and postoperative nausea and vomiting, postoperative opioid consumption in postoperative 24 hours.

Eligibility Criteria:
Inclusion Criteria:

* Adult patient, age \>19, scheduled for breast cancer surgery under general anesthesia

Exclusion Criteria:

* Patients who are not alert before procedure
* Day surgery
* BMI ≥35
* Hemodynamicaly unstable patients before procedure
* Patients with history of neromuscular disease or drug use affecting neuromuscular function.
* Patients with history of adverse reaction of allergic reaction to study drugs
* Patients who are anticipated to be unable to remove supraglottic airway or endotracheal tube due to severe dyspnea or need for mechanical ventilatory support
* Use of sedatives (anxiolytics, psychoactive medication, antidepressants, hypnotics) within 24 h
* Known galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption
* Alcohol or drug dependence
* Organic brain disorder
* Patients with hypersensitive to beans or peanut
* Patients who refuse to participate
Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis

This is a single center prospective study evaluating 124I-evuzumitide in patients with systemic amyloidosis. The purpose of this study is to 1)identify and characterize the distribution and uptake of 124I-evuzumitide in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) and 2) Correlate the uptake with the structure and function of different organs, including the heart. To achieve these goals, eligible patients will undergo primarily hybrid positron emission tomography and magnetic resonance imaging (PET/MRI). In a subgroup of patients who are unable to undergo PET/MR, computed tomography will be used instead of MRI (i.e. PET/CT). In a subgroup of patients, repeat imaging with the same modality will be done at a interval of 6-12 months. Clinically available data (demographics, phenotype, imaging, laboratory) will also be collected to characterize the disease in each patient.


Eligibility Criteria:
Inclusion Criteria:

1. Subjects will at least have one of the following conditions: systemic amyloidosis with known organ involvement, carrier of a known pathogenic mutation in the transthyretin gene, multiple myeloma, and monoclonal gammopathy of undetermined significance
2. Patient willing to consent for the study and undergo the study procedures.

Exclusion Criteria:

1. Has severe claustrophobia or any medical condition that would prevent completion of the imaging protocol
2. Has a known allergy to potassium iodide treatment or to gadolinium.
3. Patients on dialysis or those with eGFR \<30 cc/min/1.73 m2 will be excluded from undergoing gadolinium-enhanced cardiac MRI.
4. Has received heparin or heparin analogs (e.g., enoxaparin, dalteparin, fondaparinux) within 7 days prior to 124I-Evuzumitide administration
Anesthetics and Analgesics in Children

The purpose of this study is to characterize the pharmacokinetic (PK) and safety profile of anesthetics and analgesics in children and adolescents.

This is a research study to find out what the side effects are of certain drugs that are commonly used for pain and to put people to sleep for surgery. The researchers also want to know how the drug is broken down in the body. Participants will be given these drugs as they are prescribed by their regular doctor. As part of the participant's standard of care, doctors will perform tests, ask questions, review medical information and measure vital signs (heart rate, blood pressure, etc). The researchers will collect information that doctors have already written in the medical records. The research study team will collect blood from participants at certain time points depending on when the participant was first given the drug (up to 5 samples over the course of 10 to 48 hours). Examples of current and upcoming anesthetics and analgesics include, but are not limited to: ketorolac (Toradol), ketamine (Ketalar), oxycodone (OxyContin), and morphine (Kadian, MS Contin).

Eligibility Criteria:
Inclusion Criteria:

1. 0 to \<18 years of age at time of enrollment (must see applicable appendix for details as not all appendices enroll across the entire age range)
2. Parent and/or participant (if applicable) is able to understand the consent process and provides informed consent and HIPAA Authorization (if applicable)
3. Participant provides assent as required by the institutional review board (IRB) or research ethics board (REB)
4. Receiving one or more drugs of interest (DOI) per local standard of care
5. Meeting DOI-specific inclusion criteria (See Appendices)

Exclusion Criteria:

1. Known pregnancy
2. Extracorporeal life support (i.e., ECMO, dialysis, ventricular assist device)
3. Any condition which would make the participant, in the opinion of the investigator, unsuitable for the study